Key points are not available for this paper at this time.
Attention to characteristic MRI patterns, especially the presence of contrast enhancement, and the subcortical location may have utility in screening and early diagnosis of PML in natalizumab-treated MS patients.
Yousry et al. (2012) studied this question.